ClinicalTrials.gg
Not yet recruitingNCT07434466KETO-AHFUpdated Nov 9, 2026

Ketone Ester for Treatment Of Acute Heart Failure

An interventional study of Ketone Ester (KetoneAid MonoEster) and Placebo in Acute Heart Failure, sponsored by University of Alberta. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Heart Failure by University of Alberta — 11 open to participants now, 11 under way, none of them phase 3. Heart Failure · University of Alberta.

Planned enrollment
16th of 25
60 · median 100
Started
2027
with 2 others
No phase
13 of 30
5 open now
Primary completion
2027-07
later than 4 of 10 live
Registered
26th of 30
by date

Among the 30 studies in Heart Failure by University of Alberta, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2027, is one of 13 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 26th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

11 of the 30 studies in Heart Failure by University of Alberta are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Heart Failure by University of Alberta, or all of them as a file.
02

Study summary

Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.

Read the detailed description

KETO-AHF (Ketone Ester for Treatment of Acute Heart Failure) is a single-site, double-blind, randomized, placebo-controlled vanguard clinical trial evaluating the feasibility, safety, and preliminary efficacy of exogenous ketone ester therapy in adults hospitalized with acute heart failure (AHF). The trial is conducted as a domain within the Heart Failure Efficacy and Research Trial (HEART) Platform master protocol framework.

Adults (≥18 years) admitted with a primary diagnosis of acute heart failure will be screened and enrolled within 48 hours of hospital admission. Eligible participants must have dyspnea and clinical evidence of congestion and meet protocol-specified laboratory and clinical criteria, including elevated NT-proBNP and adequate kidney function (eGFR >15 mL/min/1.73m²). Key exclusions include type 1 diabetes mellitus, dialysis dependence, inability to tolerate enteral therapy, and need for advanced mechanical circulatory support or inopressor therapy.

Participants will be randomized 1:1 to receive ketone ester therapy or matching placebo for up to 5 consecutive days (or until hospital discharge or death), in addition to standard-of-care acute heart failure management. Randomization will occur through a centralized web-based system using stratified randomization by sex, and both participants and study staff will remain blinded to allocation.

The investigational intervention is KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol), administered orally or enterally at 25 g three times daily (total 75 g/day). The placebo arm receives a taste- and appearance-matched placebo administered on the same schedule. Study drug administration occurs after meals with flexibility to accommodate clinical care.

The primary endpoint is change in NT-proBNP over the treatment period. Secondary outcomes include change in heart failure symptoms using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score and change in echocardiographic measures of cardiac function. Exploratory outcomes include glycemic control and insulin requirements, renal function, daily fluid balance adjusted for diuretic dose, and clinical outcomes through 30 days including mortality and days alive and out of hospital. The vanguard design also evaluates feasibility outcomes to inform a subsequent full-scale trial, including consent rate, representation of women, intervention adherence, and follow-up completeness.

Safety monitoring includes daily clinical assessment and laboratory monitoring (including acid-base measures), with predefined adverse events of special interest and stopping rules. An independent Data Safety Monitoring Committee (DSMC) reviews safety data at prespecified enrollment intervals.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Domain-Specific Inclusion Criteria:

  1. Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, edema, or an elevated jugular venous pressure [21]
  2. Admitted to the hospital for less than 48 hours
  3. Estimated above 15 mL/min/1.73m²
  4. NT-proBNP ≥ 1000 pg/ml

Domain-Specific Exclusion Criteria:

  1. Type 1 diabetes mellitus
  2. Patients on mechanical circulatory support
  3. Patients on more than one inotrope or on inopressors
  4. Patients on dialysis
  5. Patients with non-functioning enteral tracks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    KetoneAid MonoEster

    Intervention Name: KetoneAid MonoEster Formulation: D-Beta Hydroxybutyrate bonded to R 1,3 Butanediol Dosing: 25 grams, three times per day Administration: Oral or enteral route Duration: 5 consecutive days, or until hospital discharge or death

    Dietary Supplement: Ketone Ester (KetoneAid MonoEster)

  • Placebo comparator
    Placebo

    Matching placebo, also provided by KetoneAid, with similar administration instructions.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementBeta-hydroxybutyrate-1,3-butanediol monoesterStudies of Beta-hydroxybutyrate-1,3-butanediol monoesterBeta-hydroxybutyrate-1,3-butanediol monoester pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to the intervention arm will receive KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol) administered orally or enterally at a dose of 25 g three times daily (total 75 g/day) for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

  • Dietary supplementPlacebo

    Participants randomized to the control arm will receive a matching placebo administered orally or enterally three times daily for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

06

What researchers measure

Primary outcomes

  1. Change in NT-proBNP

    Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level over the 5-day intervention period comparing ketone ester versus placebo.

    Time frame: Baseline to Day 5 (or hospital discharge if earlier)

Secondary outcomes

  1. Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)

    Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score from baseline to Day 5 comparing treatment groups. The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) ranges from 0 to 100, where higher scores indicate fewer heart failure symptoms and better health status, and lower scores indicate more severe symptoms and worse health status.

    Time frame: Baseline to Day 5 (or hospital discharge if earlier)

  2. Change in Left Ventricular Ejection Fraction (LVEF)

    Change in left ventricular ejection fraction from baseline to Day 5 comparing ketone ester versus placebo. Left ventricular ejection fraction is expressed as a percentage (%), with higher values indicating better systolic function.

    Time frame: Baseline to Day 5 (or hospital discharge if earlier)

  3. Change in Mitral Inflow E/e' Ratio

    Change in mitral inflow E/e' ratio from baseline to Day 5 comparing ketone ester versus placebo. E/e' ratio is a unitless measure of left ventricular filling pressure. Higher values indicate higher estimated filling pressures and worse diastolic function.

    Time frame: Baseline to Day 5 (or hospital discharge if earlier)

  4. Change in Stroke Volume

    Change in stroke volume from baseline to Day 5 comparing ketone ester versus placebo. Stroke volume is measured in milliliters (mL). Higher values indicate greater forward blood flow per heartbeat.

    Time frame: Baseline to Day 5 (or hospital discharge if earlier)

  5. Change in Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Change in tricuspid annular plane systolic excursion from baseline to Day 5 comparing ketone ester versus placebo. TAPSE is measured in millimeters (mm). Higher values indicate better right ventricular systolic function.

    Time frame: Baseline to Day 5 (or hospital discharge if earlier)

Other outcomes

  1. Change in serum creatinine

    Change in renal function measured by serum creatinine over the intervention period.

    Time frame: Baseline to Day 5 (or discharge if earlier)

  2. Insulin requirements

    Total insulin administered during the inpatient intervention period.

    Time frame: Day 1 through Day 5 (or discharge if earlier)

  3. Glycemic control

    Daily blood glucose measurements during the intervention period.

    Time frame: Day 1 through Day 5 (or discharge if earlier)

  4. Days Alive and Out of Hospital

    Number of days alive and out of hospital through Day 30 after randomization.

    Time frame: 30 days

  5. All-cause mortality

    All-cause mortality through Day 30 after randomization.

    Time frame: 30 days

  6. Major Adverse Kidney Events

    Composite kidney outcome through Day 30, including death, new renal replacement therapy, or persistent renal dysfunction.

    Time frame: 30 days

  7. Daily Net Fluid Balance Adjusted for Loop Diuretic Dose

    Daily net fluid balance during the inpatient intervention period (Day 1 through Day 5 or hospital discharge if earlier), adjusted for total loop diuretic dose administered. Net fluid balance will be calculated as total fluid intake minus total fluid output and normalized to loop diuretic dose received during the same period.

    Time frame: Day 1 through Day 5 (or hospital discharge if earlier)

07

Study locations

1 site
08

References and documents

Related links

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 6 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Feb 25, 2026
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Jul 2027
CompletionEst.
Mar 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
Nov 5, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: references
  2. Nov 5, 2026
    Start date Sep 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07434466
Collaborators
Canadian VIGOUR Centre, University Hospital Foundation
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Fernando G Zampieri, MD, PhD
Contact
fzampier@ualberta.ca
587-588-6151
Justin Ezekowitz, MD
Contact
jae2@ualberta.ca
780-492-0712
Fernando G Zampieri, MD, PhD
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beta-hydroxybutyrate-1,3-butanediol monoester

Start the discussion